ACSL1

Across TCGA pan-cancer cohorts, ACSL1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ACSL1 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ACSL1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACSL1 expression acts as an unfavorable survival marker.

KIRC, HNSC, and LIHC are the cancer types where ACSL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.054	0.881	<.001	46	view →
HNSC	OS	Median	All	0.150	0.685	.006	18	view →
LIHC	OS	Median	All	0.214	0.690	.008	12	view →
SARC	DFS	Median	All	0.109	0.591	.020	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.346	0.764	<.001	6	view →
ACC	OS	Median	All	0.188	0.633	.035	4	view →
SKCM	DFS	Median	All	0.500	0.733	.008	4	view →
LGG	DFS	Median	All	0.186	0.731	<.001	3	view →
COAD	OS	Median	II,III,IV	0.556	0.850	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ACSL1–KIRC (OS)

Open the KIRC breakdown →